INT129164

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.19
First Reported 2006
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 6
Total Number 6
Disease Relevance 4.46
Pain Relevance 0.57

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

cell adhesion (Cd22) plasma membrane (Cd22)
Anatomy Link Frequency
B-cell 4
Cd22 (Mus musculus)
Pain Link Frequency Relevance Heat
Inflammation 13 99.36 Very High Very High Very High
cytokine 12 98.84 Very High Very High Very High
abatacept 1 98.68 Very High Very High Very High
antidepressant 1 74.96 Quite High
fluoxetine 1 74.36 Quite High
tolerance 1 55.76 Quite High
methotrexate 6 5.00 Very Low Very Low Very Low
dexamethasone 6 5.00 Very Low Very Low Very Low
vincristine 6 5.00 Very Low Very Low Very Low
chemokine 4 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
INFLAMMATION 17 99.36 Very High Very High Very High
Apoptosis 11 98.70 Very High Very High Very High
Cancer 28 98.16 Very High Very High Very High
Lymphatic System Cancer 170 98.08 Very High Very High Very High
Necrosis 1 97.92 Very High Very High Very High
Disease 81 95.04 Very High Very High Very High
Systemic Lupus Erythematosus 37 93.28 High High
Chronic Lymphoid Leukemia 28 89.32 High High
Multiple Myeloma 16 72.80 Quite High
Acquired Immune Deficiency Syndrome Or Hiv Infection 8 68.40 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Antibodies targeting CD19, CD20, CD22, in combination with a toxin, CD23, CD40, CD80, and HLA-DR are being evaluated in clinical trials, and their additional benefit will be evaluated in coming years (DiJoseph et al 2004, 2006; Byrd et al 2005; Czuczman et al 2005; Foreno-Torres et al 2006).
CD22 Binding (combination) of
1) Confidence 0.19 Published 2008 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2727901 Disease Relevance 1.21 Pain Relevance 0
Antibodies targeting CD19, CD20, CD22, in combination with a toxin, CD23, CD40, CD80, and HLA-DR are being evaluated in clinical trials, and their additional benefit will be evaluated in coming years (DiJoseph et al 2004, 2006; Byrd et al 2005; Czuczman et al 2005; Foreno-Torres et al 2006).
CD22 Binding (targeting) of
2) Confidence 0.19 Published 2008 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2727901 Disease Relevance 1.22 Pain Relevance 0
Potential cellular and molecular targets for B-cell therapies include cell surface molecules such as CD20 (rituximab) and CD22 (epratuzumab); co-stimulatory molecules involved in B-cell-T-cell interaction such as CTLA4 and B7 molecules (abatacept); maturation and growth factors such as B-cell activating factor and a proliferation-inducing ligand (belimumab, briobacept, atacicept) and B-cell tolerogen (abetimus).
CD22 Binding (interaction) of in B-cell associated with abatacept
3) Confidence 0.13 Published 2010 Journal Int J Rheum Dis Section Abstract Doc Link 20374380 Disease Relevance 0.96 Pain Relevance 0.28
The engagement of cell surface receptors such as the B-cell receptor, receptors for inflammatory cytokines (e.g., tumor necrosis factor [TNF] ?)
B-cell receptor Binding (engagement) of in B-cell associated with necrosis, inflammation, cancer and cytokine
4) Confidence 0.07 Published 2007 Journal PLoS Pathogens Section Body Doc Link PMC1781481 Disease Relevance 0.46 Pain Relevance 0.10
Anne Krug found that PDCs synergistically enhance activation and cytokine production of human peripheral blood B cells that were stimulated by B-cell receptor ligation (anti-Ig) and a microbial molecular (CpG) [36].
B-cell receptor Binding (ligation) of in B-cell associated with cytokine
5) Confidence 0.02 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2793013 Disease Relevance 0 Pain Relevance 0.08
Lymphoma cells protected from apoptosis by dysregulated bcl-2 continue to bind annexin V in response to B-cell receptor engagement: a cautionary tale.
B-cell receptor Binding (engagement) of in B-cell associated with lymphatic system cancer and apoptosis
6) Confidence 0.01 Published 2006 Journal Leuk. Res. Section Title Doc Link 16076491 Disease Relevance 0.60 Pain Relevance 0.11

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox